---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-056920"
form_type: "8-K"
ticker: "PMN"
cik: "0001374339"
company_name: "ProMIS Neurosciences Inc."
filed_at: "2023-05-08T23:59:59+00:00"
generated_at: "2026-06-15T12:33:31.572882+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ProMIS Neurosciences receives FDA IND clearance for Alzheimer's antibody PMN310

## Summary
- FDA cleared IND for PMN310, a monoclonal antibody targeting toxic amyloid-beta oligomers in Alzheimer's disease.
- Preclinical data showed PMN310's selective binding to toxic oligomers with minimal plaque binding, potentially reducing ARIA risk.
- Company plans to initiate Phase 1a trial to evaluate pharmacokinetics, safety, and tolerability in healthy volunteers.
- CEO Gail Farfel called the clearance an important corporate milestone toward a next-generation AD therapy.

## SEC filing metadata
- accession: 0001104659-23-056920
- form_type: 8-K
- ticker: PMN
- cik: 0001374339
- company_name: ProMIS Neurosciences Inc.
- filed_at: 2023-05-08T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374339/000110465923056920/0001104659-23-056920-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374339/000110465923056920/tm2314972d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-056920
- JSON: https://secwatch.observer/filing/0001104659-23-056920.json
- Plain text: https://secwatch.observer/filing/0001104659-23-056920.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.